ADC therapy

TF ADC Competition Accelerates: Zai Ding Files for Cervical Cancer Approval, Xin Nuo Wei Launches Phase III for Pancreatic Cancer

by
TF ADC Competition Accelerates: Zai Ding Files for Cervical Cancer Approval, Xin Nuo Wei Launches Phase III for Pancreatic Cancer

Click the blue text Follow us This Issue Highlights Currently, the only approved TF-ADC drug globally is Seagen’s TIVDAK (tisotumab vedotin-tftv, for cervical cancer), with a carrier of VA–MMAE. It has been approved for sale in Japan. The domestic sales are handled by Zai Ding Pharmaceutical, which has submitted a listing application. Xin Nuo Wei’s … Read more

ESMO: DS-8201 Advances in Second-Line Treatment for HER2-Positive Gastric Cancer

by
ESMO: DS-8201 Advances in Second-Line Treatment for HER2-Positive Gastric Cancer

On September 10, 2022, updated data from the open-label, multicenter Phase II DESTINY-Gastric02 study were presented at the ESMO conference, showing that DS-8201 demonstrated sustained clinical benefits and acceptable safety in patients with locally advanced or metastatic HER2-positive gastric cancer or gastroesophageal junction (GEJ) cancer who had previously received trastuzumab-based therapy. The study included 79 … Read more